アルツハイマー病市場：KOLの洞察

当レポートでは、世界のアルツハイマー病市場について調査し、市場の概要とともに、上市済み治療法、パイプライン動向、将来の見通しなどを提供しています。

目次

エグゼクティブサマリー

現在および将来の治療アルゴリズム

調査目的

最近承認された治療法

• 抗アミロイドベータ（A-ベータ）モノクローナル抗体（mAb）
  • 重要な洞察の概要
  • アデュヘルム（アデュカヌマブ、バイオジェン/神経免疫療法）
  • レケンビ（レカネマブ;BioArctic/エーザイ/バイオジェン）

パイプライン製品

• 抗アミロイドベータ（A-ベータ）モノクローナル抗体
• アミロイドβタンパク質阻害剤/GABA A受容体アゴニスト
• ペプチド加水分解酵素阻害剤
• ムスカリン受容体モジュレーター/シグマ-1受容体アゴニスト
• マイクロフィラメントタンパク質モジュレーター
• 肝細胞増殖因子刺激薬
• ムスカリン性（M1/M4）受容体薬剤
• シヌクレイン阻害剤/タウタンパク質阻害剤
• IL23、IL6阻害剤/MAPK3/MAPK1阻害剤/NF-κB阻害剤/TNF阻害剤
• グルカゴン様ペプチド1受容体アゴニスト
• 5型環状ヌクレオチドホスホジエステラーゼ阻害剤
• アセチルコリンエステラーゼ阻害剤/ニコチン性受容体モジュレーター
• 5-HT1セロトニン受容体作動薬/メラトニン受容体作動薬/セロトニン1D/2B受容体作動薬

初期段階の見通し

• 重要な洞察の概要
  • ABBV 916（アミロイドベータタンパク質阻害剤;AbbVie）
  • ACI 24（抗Aβワクチン、AC Immune）
  • ACI 35.030（リポソーム抗pTauワクチン;AC Immune/Janssen Pharmaceuticals）
  • AEF 0217（カンナビノイド受容体CB1アンタゴニスト;Aelis Farma）
  • AL-002（TREM2タンパク質刺激薬;Alector）
  • ALN APP（RNA干渉、Alnylam Pharmaceuticals）
  • AV 1959D（DNAベースのエピトープワクチン、Capo Therapeutics）
  • ベプラネマブ（タウタンパク質阻害剤;UCB Biopharma/Roche）
  • BIIB 080（IONIS-MAPTRX/アンチセンスタウタンパク質阻害剤;Biogen/Ionis Pharmaceuticals）
  • Elcubragistat（モノアシルグリセロールリパーゼ阻害剤;Abide Therapeutics/Lundbeck A/S）
  • ペピネマブ（CD100抗原阻害剤、Vaccinex）
  • ヴァログルタムスタット;（グルタミニルペプチドシクロトランスフェラーゼ阻害剤;Vivoryon Therapeutics）
  • コントラロイド（アミロイドβタンパク質阻害剤;Priavoid）
  • PRX012（抗A-β抗体、Prothena）
  • セモリネマブ（抗タウ抗体;AC Immune/Roche）
  • テルトモチド（テロメラーゼペプチドワクチン;Pharmexa/KAEL-GemVax/Samsung Pharm）

付録

While KOLs say BioArctic/Biogen/Eisai's Leqembi is set to dominate AD therapy, what are the dosing, cost and reimbursement challenges that could impact takeup? Eli Lilly's next-generation late-stage anti-amyloid therapy donanemab is eagerly anticipated, but what clinical advantages and challenges do experts identify, and how might it impact Leqembi? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users can access the following KOL Bulletins via the Attachments area.

Key questions answered:

• Biogen's Aduhelm was seen as a trailblazer in AD therapy but has failed to live up to expectations - how do KOLs assess the failure?
• How might Eli Lilly's remternetug offer better patient convenience and the possibility of home-based administration?
• How do KOLs assess the potential of Roche's innovative Brainshuttle approach for trontinemab?
• Tau remains an attractive target, so why are KOLs sceptical about the prospects for Annovis Bio's Posiphen and TauRx's LMTX?
• How do KOLs assess pipeline therapies which do not target amyloid and tau pathways, such as AlphaCognition's Alpha 1062, AriBio's AR 1001, Karuna Therapeutics' KarXT and BioVie's NE3107?
• Why is KOL opinion split on the prospects for Alzheon's niche pipeline therapy valiltramiprosate?

Key brands covered in this report:

Table of Contents

Executive summary (6)

Current and future treatment algorithm

Research objectives (2)

Recently approved therapies (19)

• Anti-amyloid beta (A-Beta) monoclonal antibodies (mAbs) (19)
  • Key insights summary (2)
  • Aduhelm (aducanumab; Biogen/Neurimmune Therapeutics) (1)
  • Leqembi (lecanemab; BioArctic/Eisai/Biogen) (16)

Pipeline products (104)

• Anti-amyloid beta (A-Beta) mAbs (19)
  • Key insights summary (2)
  • LY 3002813 (donanemab; Eli Lilly & Co.) (1)
  • LY-3372993 (remternetug; Eli Lilly & Co.) (1)
  • RG-6102 (trontinemab; Roche) (15)
• Amyloid beta-protein inhibitors/GABA A receptor agonists (7)
  • ALZ 801 (valiltramiprosate; BELLUS Health/FB Health/Alzheon) (7)
• Peptide hydrolase inhibitors (6)
  • COR-388 (atuzaginstat; Lighthouse Pharmaceuticals) (6)
• Muscarinic receptor modulators/Sigma-1 receptor agonists (6)
  • Blarcamesine (Anavex Life Sciences) (6)
• Microfilament protein modulators (6)
  • Filora (simufilam; Cassava Sciences) (6)
• Hepatocyte growth factor stimulants (8)
  • Fosgonimeton (Athira Pharma) (8)
• Muscarinic (M1/M4) receptor agents (7)
  • KarXT (trospium chloride/xanomeline; Karuna Therapeutics [BMS]) (7)
• Synuclein inhibitors/Tau protein inhibitors (10)
  • Key insights summary (2)
  • LMTX (hydromethylthionine mesylate; TauRx Pharmaceuticals) (1)
  • Posiphen (buntanetap; Annovis Bio) (7)
• IL23, IL6 inhibitors/MAPK3/MAPK1 inhibitors/NF-kB inhibitors/TNF inhibitors (9)
  • NE3107 (BioVie) (9)
• Glucagon-like peptide 1 receptor agonists (8)
  • Rybelsus (semaglutide oral; Novo Nordisk) (8)
• Type 5 cyclic nucleotide phosphodiesterase inhibitors (4)
  • AR 1001 (AriBio) (4)
• Acetylcholinesterase inhibitors/Nicotinic receptor modulators (7)
  • Alpha 1062 (benzgalantamine; AlphaCognition) (7)
• 5-HT1 serotonin receptor agonists/Melatonin receptor agonists/Serotonin 1D/2B receptor agonists (7)
  • Neu-P11 (piromelatine; Neurim Pharmaceuticals) (7)

Early-stage prospects (21)

• Key insights summary (21)
  • ABBV 916 (amyloid beta-protein inhibitor; AbbVie) (1)
  • ACI 24 (anti-Abeta vaccine; AC Immune) (1)
  • ACI 35.030 (liposomal anti-pTau vaccine; AC Immune/ Janssen Pharmaceuticals) (1)
  • AEF 0217 (cannabinoid receptor CB1 antagonist; Aelis Farma (1)
  • AL-002 (TREM2 protein-stimulant; Alector) (1)
  • ALN APP (RNA interference; Alnylam Pharmaceuticals) (1)
  • AV 1959D (DNA based epitope vaccine; Capo Therapeutics) (1)
  • Bepranemab (Tau protein inhibitor; UCB Biopharma/Roche) (1)
  • BIIB 080 (IONIS-MAPTRX/antisense Tau protein inhibitor; Biogen/Ionis Pharmaceuticals) (1)
  • Elcubragistat (monoacylglycerol lipase inhibitor; Abide Therapeutics/Lundbeck A/S) (1)
  • Pepinemab (CD100 antigen inhibitors; Vaccinex) (1)
  • Varoglutamstat; (glutaminyl-peptide cyclotransferase inhibitor; Vivoryon Therapeutics) (1)
  • Contraloid (amyloid beta-protein inhibitor; Priavoid) (1)
  • PRX012 (anti-A-Beta antibody; Prothena) (1)
  • Semorinemab (anti-tau antibody; AC Immune/Roche) (1)
  • Tertomotide (telomerase peptide vaccine; Pharmexa/KAEL-GemVax/Samsung Pharm) (4)

Appendix (5)

• KOL details (5)
  • KOLs from North America (1)
  • KOLs from Europe (3)